To propose a prevention of mother-to-child transmission (PMTCT) care continuum that defines the programmatic steps necessary to provide HIV care to the HIV-infected pregnant woman and her infant during the risk period for HIV transmission.
INTRODUCTION
Over the past decade, the scale-up of prevention of mother-to-child transmission (PMTCT) services in resource-limited settings has been remarkable with substantial increases in coverage rates of HIV testing and receipt of antiretroviral (ANV) drugs among pregnant and breastfeeding women [1] . As a result of these efforts, between 2009 and 2013 globally there was an estimated 40% reduction in vertical transmission of HIV [2] . Nonetheless, there were 240 000 new infections among children in lowincome and middle-income countries in 2013, and more than 20 countries globally that have perinatal rates above 30% [2] .
In 2013, WHO Guidelines recommended triple antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women, regardless of the woman's CD4 þ cell count, referred to as the Option Bþ approach [3] . The goal of Option Bþ is to increase ART coverage during pregnancy and breastfeeding, ensure that all ART eligible women initiate treatment, and further reduce vertical transmission. This approach has streamlined the PMTCT care continuum, avoiding the need for laboratory assessment for ART eligibility and simplifying ANV options to triple drug therapy for all pregnant women rather than tailoring ANV options based on the woman's HIV disease stage.
Most high-prevalence countries such as South Africa, Uganda, and Zambia are adopting Option Bþ nationally. Malawi was the first country to introduce Option Bþ in late 2011 and quickly demonstrated enormous success in expanding ART access across the country and dramatically increasing the number of HIV-infected pregnant women starting ART. In the first quarter of implementation, there was a 748% increase in the number of HIV-infected pregnant women who started lifelong treatment. By the third quarter of 2012, pregnant women composed of 35% of all adults initiated on ART in the country [4] .
Although Option Bþ appears to have improved the number of pregnant women initiating ART, the progress of PMTCT programs toward eliminating vertical HIV transmission and achieving desired health outcomes for HIV-infected women and their infants is dependent on many steps beyond just initiation of ART. Suboptimal retention in PMTCT care continues to threaten efforts to prevent new pediatric infections. In a study conducted in Malawi, attrition of pregnant women in 540 health facilities providing Option Bþ was 17% within 6 months of ART initiation, with five-fold higher risk of attrition [adjusted odds ratio (OR) 5.0, 95% confidence interval (CI) 4.2-6.1] among women starting ART during pregnancy as compared with women with advanced disease initiating treatment for their own health [5 & ]. The PMTCT care continuum is a framework of essential steps that are needed for both the pregnant woman and her infant in order to achieve the desired outcome of HIV-free survival and optimal retention, adherence, and viral load suppression among the HIV-infected woman. In this article, we propose a PMTCT care continuum that consists of two interlinked continua of care -one for the HIV-infected woman and one for her child -and discuss complexities in effective engagement of women and infants in and across each step of the continua that must be addressed to optimize maternal and child health outcomes.
THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION CARE CONTINUUM
PMTCT care involves two persons -the pregnant woman and her infant -motivating the need for two interlinked PMTCT continua, one focusing on maternal care and the other highlighting key steps across the child's continuum of care.
Maternal prevention of mother-to-child transmission continuum
Identification of HIV infection in pregnant women is a critical step in the prevention of MTCT. As noted in Fig. 1 , HIV testing is the first step in the maternal PMTCT continuum. All pregnant women should be provided opt-out HIV testing during antenatal care (ANC), with repeat testing at delivery of those who test negative and repeat testing of negative women with each additional pregnancy [6] . In a review of 44 studies from 15 countries in sub-Saharan Africa,
KEY POINTS
This study presents a PMTCT care continuum that defines the programmatic steps necessary to provide HIV care to the HIV-infected pregnant woman and her infant during the risk period for HIV transmission.
The proposed PMTCT care continuum addresses several complexities of PMTCT care, including the evolution in the population of women entering PMTCT care, various models of PMTCT service delivery and patterns of PMTCT care, and the critical step of transfer of women's HIV care from PMTCT programs to adult HIV clinics.
A combined outcome across the continuum of maternal viral load suppression and HIV-free infant survival is encouraged and emphasizes the desired impact of PMTCT programs on maternal and child health longterm outcomes. 
Outcomes of ART in different populations
HIV-testing uptake at ANC was 94% (95% CI 92-95) for opt-out testing as compared with 58% (95% CI 40-75) with an opt-in approach [7] . The adoption of routine provider-initiated HIV testing and counseling within ANC has facilitated progress toward universal testing among pregnant women [8] . It is also important to note that pregnancy and the postpartum period are times of high risk for HIV acquisition, which confer significantly increased risk of MTCT as well [9 & ]. Therefore, detection of HIV should be prioritized through repeat testing at delivery and during breastfeeding in high HIV prevalence settings [10] [11] [12] .
The second step in the continuum is prompt ART initiation among HIV-infected pregnant women as soon as possible after HIV diagnosis and as early as possible in the course of pregnancy. Studies have shown that longer duration of ART use by the woman during pregnancy is correlated with a reduced risk of transmission to the infant [13 & , 14, 15] . Over the past several years there have been changes in the models of care for ART delivery to HIV-infected pregnant women. The training of nurses and other nonphysician cadres to prescribe ART in the ANC setting, in contrast to referring ART eligible pregnant women to adult HIV clinics to initiate treatment, has expedited ART initiation and been associated with reduced loss to followup among pregnant women. A study conducted in South Africa reported that integration of ART into ANC was associated with increases in the proportion of eligible pregnant women starting ART and shorter time to start ART, with 82% of women initiating ART at their first ANC visit [16 & ]. The third step in the continuum involves retention of women in PMTCT care and support of adherence to ART throughout the course of the pregnancy and breastfeeding periods. Retention in care is critical for management of ART side-effects and treatment failure, prevention of opportunistic infections, and in some settings receipt of reproductive health services. Adherence to ART during pregnancy and breastfeeding is essential for prevention of MTCT, as maternal viral load is the primary determinant of risk of the infant acquiring HIV infection [17] . The fourth step in the continuum involves the woman's transfer of HIV care from PMTCT services, generally provided in ANC clinics, to adult HIV care and treatment, which is often located in a different clinic location in order to ensure that the women continue to receive lifelong HIV care. Depending on how services are organized in specific settings, transfer of care can take place during pregnancy, after delivery, or after cessation of breastfeeding when perinatal transmission risk ends (Fig. 2) . The ultimate step in the maternal continuum is maintenance of lifelong viral suppression, which is critical for longterm health of the mother and only achieved through adherence to treatment and retention in care.
Although often not recognized as a component of the PMTCT care continuum, pregnant women who test HIV-negative should be provided with HIV prevention services, which are generally available at clinic locations outside of the maternal-child health setting. Services include partner testing, condom use, and repeat HIV testing.
Infant prevention of mother-to-child transmission continuum
The first step in the infant PMTCT continuum is initiation of ARV prophylaxis within hours of birth ( Fig. 3 ). WHO guidelines recommend 6-12 weeks of daily ARVs for all HIV-exposed infants independent of maternal ART regimen (3). The second step is virologic testing, early infant diagnosis, which should be done at 6 weeks of age to determine if the exposed infant is HIV-infected. Virologic testing, with HIV RNA, DNA, or total nucleic acid, can be utilized to detect the HIV virus and distinguish HIV exposure, as evidenced by presence of maternal HIV antibodies that cross the placenta, from HIV infection. Based on the result of the virologic test, the continuum for infants varies. Infants determined to have a positive virologic test must be transferred to pediatric HIV care and treatment services, where ART is promptly initiated in order to prevent the early morbidity and mortality of untreated HIV infection in infants [18] . Infants must then be retained in HIV care where they can be monitored for growth, development, and treatment side-effects, and receive prophylaxis for opportunistic infections and support for optimal ART adherence. The final step in the continuum for HIVinfected infants and children is viral load suppression and retention in lifelong care, similar to their mothers.
For infants who have a negative virologic test at 6 weeks, it is critical that they remain in care until 18 months of age or until after weaning, whichever is later, when final HIV status can be assessed. These infants need to be monitored for growth and development and for evidence of HIV disease, and then retested for infection, typically by HIV antibody testing. Infants found to be infected must be rapidly linked to pediatric HIV care and treatment services and initiated on ART whereas those who test negative are linked to routine well child pediatric care. The ultimate endpoint for the uninfected infants is HIV-free survival, typically measured at 18-24 months after birth.
COMPLEXITIES OF THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION CARE CONTINUUM
The proposed interlinked PMTCT continuum acknowledges several complexities in PMTCT care, which have not previously been featured, including the evolution of the population of women entering PMTCT care, various models of PMTCT service delivery and patterns of PMTCT care, and the need for a new step in the PMTCT continuum accounting for the transfer of the woman's HIV care from PMTCT programs to adult HIV care and treatment services. We also propose consideration of a combined final outcome for the woman and the child across an interlinked PMTCT continuum.
The evolution of the population of women entering prevention of mother-to-child transmission care
The traditional PMTCT care continuum begins with testing of pregnant women during ANC. However, the scale-up of HIV services over the past decade has resulted in more women who are already known to be HIV infected and engaged in HIV care who become pregnant. Such women are referred to PMTCT programs for ANC and initiation of ART for prevention of vertical transmission, if not already receiving it for their own health. As these women were already in HIV care prior to the pregnancy, the decision as to where they will continue to receive HIV care and treatment during pregnancy and postnatally during breastfeeding will depend on how services are organized -options may include Variation in prevention of mother-to-child transmission models and patterns of care ] describe several PMTCT Option Bþ 'models of care' in Malawi, which include all PMTCT care including ART provided in the ANC clinic, women initiating ART in the ANC clinic with referral to the adult HIV clinic for ongoing ART throughout pregnancy, women referred from the ANC clinic to the adult HIV clinic for ART initiation and follow-up throughout pregnancy, and women initiating ART in an ANC or an adult HIV clinic with referral to another HIV clinic for ongoing ART throughout pregnancy. However, these models focus primarily on the antenatal period with less attention given to the postpartum period, an equally important period when adherence to ART and retention in care are critical for the woman and for prevention of HIV transmission during breastfeeding [21] .
A second complexity in PMTCT care is the fact that pregnant women may migrate to their home communities seeking support from their families during delivery and the postpartum period. Some may return back with their infants and continue care at their primary clinics, whereas others may choose to continue care elsewhere or leave their infants with family members. These often time-limited periods of migration are difficult to document within the PMTCT care continuum. Using the lexicon of the adult HIV care continuum, such gaps in care among women who leave and return to HIV care are referred to as a 'side door' [22] . HIV programs should strengthen counseling among women who wish to migrate during the MTCT risk period in order to avoid treatment interruptions, rebound viremia, and health threats to both the woman and her baby. Should the woman choose to transfer HIV care during pregnancy, robust communication between staff members in the various clinics, including documentation of necessary information, must occur to ensure women receive ongoing PMTCT care and to minimize misclassification of losses to care.
Transfer of maternal HIV care from prevention of mother-to-child transmission to adult HIV services
Typically, the PMTCT care continuum has focused on the steps involved in determining the final HIV status of the exposed infant and only included steps in the mother's pathway of care as related to that outcome [23] [24] [25] . The continuum must be expanded to include the transfer of the mother's HIV care from PMTCT services to adult HIV care and treatment as this step is essential for optimal health outcomes of the mother and for prevention of HIV transmission during future pregnancies and to her sexual partners. Depending on an HIV program's model of care, transfer can happen early (if ART is administered in the ART clinic during pregnancy), after delivery (if ART is integrated into ANC services), or at end of MTCT risk period/after weaning (if ART is integrated with infant postnatal follow-up; Fig. 2) . Currently, there are no guidelines for the timing or criteria for transfer, and generally no monitoring tools for measuring this step in either PMTCT or HIV programs [21] . Moreover, there are large programmatic differences between PMTCT and adult HIV clinics, which pose challenges for successful transfer. These include differences in clinic locations (ANC vs. adult HIV clinics), staffing, clinic patient volume, waiting times, and support and peer serv-
]. Few studies have included this important transfer step [23, 27] , which has gained more importance as increasing numbers of pregnant women initiate ART with Option Bþ and thus must continue lifelong treatment.
Consideration of a combined outcome for the prevention of mother-to-child transmission care continuum Traditionally, PMTCT program outcomes include an estimate of early vertical transmission, the number of new pediatric infections detected with early infant diagnosis, in addition to process measures for earlier steps in the continuum such as number of pregnant women tested and number who initiated ART [6,28 & ]. A limitation of using the number of infants infected as the key outcome of the PMTCT care continuum is that it does not take into account the women and infants who are lost from the continuum prior to getting virologic testing at 6 weeks. Such losses to follow-up may be because of pregnancy-related mortality, stillbirths, miscarriages, newborn and infant mortality, and mother/baby disengagement from care [29 & ].
Another limitation of this endpoint is that it only acknowledges the early outcome for the infant, while failing to account for ongoing HIV transmission risk to the child during breastfeeding. Furthermore, the focus on the child does not take into account the outcome of the HIV-infected woman. In many countries with high HIV prevalence, maternal mortality remains high [30] with HIV infection being associated with a six-fold increased risk of maternal mortality [31] .
To respond to the need for a more comprehensive indicator, we propose an ambitious combined PMTCT outcome that includes both HIV-free survival for the infant and sustained viral load suppression for the mother. HIV-free survival is an outcome commonly used in PMTCT research and is defined as a child being alive and HIV-free at the time of final HIV testing (typically at 18 or 24 months) [32, 33] . A combined outcome that is also relevant to the longterm health of the mother raises the bar for PMTCT programs with 'no partial credit' given for achievement of only one endpoint either for the woman or the child [34] . The advantage of such a combined outcome is that it promotes a systems perspective, highlights the context of pregnancy which is a transient event in a chronic lifelong disease, and uses a maternal-child health approach by underscoring the impact of PMTCT programs on achievement of future maternal and child health outcomes [34, 35] . Furthermore, it underscores global efforts to eliminate new pediatric HIV infections and reach the ambitious new 90.90.90 targets set by UNAIDS [36, 37] . Finally, a combined outcome shifts attention from counting infections to measuring survival and would indicate that PMTCT programs are implementing all of the services required to achieve optimal outcomes for both women and infants. In order to operationalize the measurement of this outcome, HIV programs and funders will need to embrace this approach and to establish systems to collect information to derive this combined indicator.
CONCLUSION
Although PMTCT programs have made impressive strides in decreasing the number of HIV-infected children globally, there is still vast need for continued improvement in PMTCT program performance in order to achieve an AIDS-free generation. To further optimize PMTCT care, we propose a reconceptualization of the PMTCT care continuum to include two interlinked continua -one for the HIV-infected mother and one for her infant. We also propose a combined outcome across the continuum of maternal viral load suppression and HIV-free infant survival, which emphasizes the desired impact of PMTCT programs on maternal and child health long-term outcomes. This study compared integrated HIV and ANC care within the ANC setting (6 clinics, 569 women) with nonintegrated care in which PMTCT services were provided in the ANC setting but women were referred to HIV care at the HIV clinic within the same facility (6 clinics 603 women) in rural Kenya on PMTCT outcomes. The clinics randomized to integrated care, as compared with nonintegrated care, had higher enrolment in HIV care (OR 3.94, 95% CI 1.14-13.63), shorter median time to enrolment (0 vs. 8 days, hazard ratio 2.20, 95% CI 1.62-3.01), and a higher proportion of eligible women initiated ART (40 vs. 17%, OR 3.22, 95% CI 1.81-5.72). In addition, infant testing was more common in the integrated clinics (25 vs. 18%, not statistically different). This retrospective cohort study reports PMTCT outcomes among 31 504 women who received PMTCT services in 31 clinical sites in Nigeria from 2004 to 2014. A total of 66% of women completed the entire cascade of services. The largest loss of women (21%) in the cascade occurred prior to delivery. A further loss of 16% of women occurred prior to the first infant visit. Among the 20 202 (53%) infants with available HIV DNA PCR results, the rate of HIV transmission for infants whose mothers received any antenatal and/or delivery care was 2.8% versus 20.0% if their mothers received none.
